Search Result

Results for "

MT2 receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (11) Drug Metabolite (2) Endogenous Metabolite (7) Isotope-Labeled Compounds (3) Melatonin Receptor (30) P2X Receptor (2) Reference Standards (3) Sodium Channel (2) TRP Channel (2)
By Research Areas:	Cancer (3) Endocrinology (6) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (28)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-133113

7-Desmethyl-agomelatine 1 Publications Verification	5-HT Receptor	Neurological Disease
7-Desmethyl-agomelatine is a metabolite of Agomelatine. Agomelatineis a potent agonist at melatonin receptors (MT1 and MT2), and also is an antagonist of 5-HT2C .

HY-101358

8-M-PDOT AH-002	Melatonin Receptor	Neurological Disease
8-M-PDOT (AH-002) is a selective melatonin MT2 receptor agonist. 8-M-PDOT is 5.2-fold selective for *MT2* over MT1 receptors. 8-M-PDOT binds human recombinant *MT2* and MT2 receptors with pKi values of 8.23 and 8.95 respectively. 8-M-PDOT has anxiolytic-like activity .

HY-17038S

Agomelatine-d6 S-20098-d₆	Isotope-Labeled Compounds Melatonin Receptor 5-HT Receptor	Neurological Disease
Agomelatine-d₆ is deuterium labeled Agomelatine. Agomelatine is a specific agonist of MT1 and MT2 receptors[1] .

HY-101254

Luzindole Maximum Cited Publications 12 Publications Verification N-0774	Melatonin Receptor	Neurological Disease
Luzindole (N-0774) is a selective melatonin receptor antagonist. Luzindole preferentially targets MT2 (Mel_1b) over MT1 (Mel_1a) with K_i values of 10.2 and 158 nM for human MT2 and MT1, respectively. Luzindole suppresses experimental autoimmune encephalomyelitis (EAE), and exerts antidepressant-like activity .

HY-101074

UCM 608 2-Phenylmelatonin	Melatonin Receptor	Neurological Disease Inflammation/Immunology Cancer
UCM 608 is a high affinity melatonin (MT) membrane receptor agonist. The pKi values for MT1 and *MT2* are 10.7 and 10.4 .

HY-138626

ACH-000143	Melatonin Receptor	Metabolic Disease
ACH-000143 is a potent and orally active melatonin receptor agonist, with EC₅₀ values of 0.06 nM and 0.32 nM for MT1 and MT2, respectively .

HY-119010

UCM 549	Melatonin Receptor	Neurological Disease
UCM 549 is a melatonin MT2 receptor inverse agonist and a MT1 receptor antagonist .

HY-131947

DH97-7	Melatonin Receptor	Neurological Disease
DH97 is a potent melatonin receptor 2 (MT2) antagonist with K_i values of 252 nM and 1100 nM for MT2 and MT1, respectively .

HY-107628

N-Pentanoyl 2-benzyltryptamine	Melatonin Receptor	Neurological Disease
N-Pentanoyl 2-benzyltryptamine is a potent and selective antagonist of **MT₂ melatonin receptor, with a pK_i** of 8.03 for human MT₂. N-Pentanoyl 2-benzyltryptamine shows 89- and 229-fold selectivity for human MT₂ over human mt₁ and Xenopus mel_1c receptor subtypes. N-Pentanoyl 2-benzyltryptamine can inhibit melatonin-induced enhancement of electrically-evoked responses .

HY-147542

*Melatonin receptor* agonist 1**	Melatonin Receptor	Neurological Disease
Melatonin receptor agonist 1 (compound 20c) is a potent melatonin receptor (MT) agonist, with K_i values of 108 nM (MT₂) and 1140 nM (MT₁) .

HY-101254R

Luzindole (Standard) N-0774 (Standard)	Reference Standards Melatonin Receptor	Neurological Disease
Luzindole (Standard) is the analytical standard of Luzindole. This product is intended for research and analytical applications. Luzindole (N-0774) is a selective melatonin receptor antagonist. Luzindole preferentially targets MT2 (Mel1b) over MT1 (Mel1a) with Ki values of 10.2 and 158 nM for human MT2 and MT1, respectively. Luzindole suppresses experimental autoimmune encephalomyelitis (EAE), and exerts antidepressant-like activity .

HY-100609

4-P-PDOT 5+ Cited Publications	Melatonin Receptor	Neurological Disease
4-P-PDOT is a potent, selective and affinity Melatonin receptor (MT2) antagonist. 4-P-PDOT is >300-fold more selective for *MT2* than MT1. 4-P-PDOT significantly counteracts Melatonin-mediated antioxidant effects (GSH/GSSG ratio, phospho-ERK, Nrf2 nuclear translocation, Nrf2 DNA-binding activity) .

HY-103005

Ramelteon metabolite M-II	Melatonin Receptor Drug Metabolite	Neurological Disease Endocrinology
Ramelteon metabolite M-II is the major metabolite of Ramelteon, with IC₅₀s of 208 pM, 1470 pM for human melatonin receptors (MT₁ or MT₂). Ramelteon is a selective melatonin agonist.

HY-100609R

4-P-PDOT (Standard)	Reference Standards Melatonin Receptor	Neurological Disease
4-P-PDOT (Standard) is the analytical standard of 4-P-PDOT. This product is intended for research and analytical applications. 4-P-PDOT is a potent, selective and affinity Melatonin receptor (MT2) antagonist. 4-P-PDOT is >300-fold more selective for MT2 than MT1. 4-P-PDOT significantly counteracts Melatonin-mediated antioxidant effects (GSH/GSSG ratio, phospho-ERK, Nrf2 nuclear translocation, Nrf2 DNA-binding activity) .

HY-101176

2-Iodomelatonin 2 Publications Verification	Melatonin Receptor	Cancer
2-Iodomelatonin is a potent agonist of *melatonin receptor* 1 (MT1) with a K_i** value of 28 pM, it is more 5-fold selective for MT₁ over MT₂ . 2-iodomelatonin can be used to identify, characterize and localize melatonin binding sites in the brain and peripheral tissues .

HY-14803

Tasimelteon BMS-214778; VEC-162	Melatonin Receptor	Neurological Disease Endocrinology
Tasimelteon (BMS-214778) is an orally active and selective *dual melatonin receptor* agonist (DMRA)*. Tasimelteon has 2.1-4.4 times greater affinity for the MT2* receptor than for the MT1 receptor. Tasimelteon is a circadian regulator and has the potential for Non-24-Hour Sleep-Wake Disorder (Non-24) .

HY-103005S

Ramelteon metabolite M-II-d3	Melatonin Receptor Drug Metabolite	Neurological Disease Endocrinology
Ramelteon metabolite M-II-d₃ is the deuterium labeled Ramelteon metabolite M-II. Ramelteon metabolite M-II is the major metabolite of Ramelteon, with IC50s of 208 pM, 1470 pM for human melatonin receptors (MT1 or MT2). Ramelteon is a selective melatonin agonist[1][2].

HY-115861

UCM765	Endogenous Metabolite	Neurological Disease
UCM765 is a selective MT2-type melatonin receptor ligand with hypnotic, analgesic and anxiolytic activities. The partial agonist effect of UCM765 has attracted attention in pharmacological studies. By structurally modifying UCM765, its water solubility and metabolic stability can be improved, thereby increasing its bioavailability. The biological activity of UCM765 has been verified in a rat model, supporting its potential for further pharmacological studies .

HY-14803S

Tasimelteon-d5 BMS-214778-d₅; VEC-162-d₅	Isotope-Labeled Compounds Melatonin Receptor	Neurological Disease Endocrinology
Tasimelteon-d₅ is the deuterium labeled Tasimelteon. Tasimelteon (BMS-214778) is an orally active and selective dual melatonin receptor agonist (DMRA). Tasimelteon has 2.1-4.4 times greater affinity for the MT2 receptor than for the MT1 receptor. Tasimelteon is a circadian regulator and has the potential for Non-24-Hour Sleep-Wake Disorder (Non-24)[1][2].

HY-100940

6-Chloromelatonin	Melatonin Receptor	Endocrinology
6-Chloromelatonin is a potent melatonin receptor agonist with greater metabolic stability than melatonin. 6-Chloromelatonin compete for [ ³H]-melatonin and 2-[ ¹²⁵I]-iodomelatonin binding to MT1 receptors (pK_i=8.9 and 9.1, respectively). 6-Chloromelatonin compete for [ ³H]-melatonin binding to MT2 receptors (pK_i=9.77) .

HY-14803R

Tasimelteon (Standard)	Melatonin Receptor	Neurological Disease Endocrinology
Tasimelteon (Standard) is the analytical standard of Tasimelteon. This product is intended for research and analytical applications. Tasimelteon (BMS-214778) is an orally active and selective *dual melatonin receptor* agonist (DMRA)*. Tasimelteon has 2.1-4.4 times greater affinity for the MT2* receptor than for the MT1 receptor. Tasimelteon is a circadian regulator and has the potential for Non-24-Hour Sleep-Wake Disorder (Non-24) .

HY-114962

S-22153	Melatonin Receptor	Neurological Disease
S-22153 is a potent melatonin receptor antagonist with EC₅₀ values of 19 nM, 4.6 nM for hMT₁ and hMT₂ melatonin receptor, respectively. S-22153 has K_i values of 8.6 nM (CHO cells) and 16.3 nM (HEK cells) for hMT₁, and 6.0 nM (CHO cells) and 8.2 nM (HEK cells) for hMT₂. S-22153 is a specific ligand of MT₁ and MT₂ melatonin receptors subtypes .

HY-101176R

2-Iodomelatonin (Standard)	Reference Standards Melatonin Receptor	Cancer
2-Iodomelatonin (Standard) is the analytical standard of 2-Iodomelatonin. This product is intended for research and analytical applications. 2-Iodomelatonin is a potent agonist of melatonin receptor 1 (MT1) with a Ki value of 28 pM, it is more 5-fold selective for MT1 ?over MT2 . 2-iodomelatonin can be used to identify, characterize and localize melatonin binding sites in the brain and peripheral tissues .

HY-106136

TIK-301 PD-6735; LY-156735	Melatonin Receptor 5-HT Receptor	Neurological Disease
TIK-301 (PD-6735) is a chlorinated melatonin derivative and a potent, high-affinity and orally active melatonin MT₁ and **MT₂ receptors agonist with K_i*s of 0.081 nM and 0.042 nM, respectively. TIK-301 is also a 5-HT_2B/5-HT_2C receptors* antagonist with antidepressant action. TIK-301 has the potential for sleep disorders and other circadian rhythm disorders treatment .

HY-17038A

Agomelatine hydrochloride 4 Publications Verification S-20098 hydrochloride	Melatonin Receptor 5-HT Receptor Endogenous Metabolite	Neurological Disease
Agomelatine hydrochloride (S-20098 hydrochloride) is a specific agonist of MT1 and *MT2* receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine hydrochloride is a selective 5-HT2C receptor antagonist with pK_is of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively .

HY-17038

Agomelatine 4 Publications Verification S-20098	Melatonin Receptor 5-HT Receptor Endogenous Metabolite	Neurological Disease
Agomelatine (S-20098) is a specific agonist of MT1 and *MT2* receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine is a selective 5-HT2C receptor antagonist with pK_is of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively .

HY-105285

Piromelatine Neu-P11	Melatonin Receptor 5-HT Receptor P2X Receptor TRP Channel Sodium Channel	Neurological Disease
Piromelatine (Neu-P11) is a melatonin MT₁/MT₂ receptor agonist, serotonin 5-HT_1A/5-HT_1D agonist, and serotonin 5-HT_2B antagonist. Piromelatine (Neu-P11) possesses sleep promoting, analgesic, anti-neurodegenerative, anxiolytic and antidepressant potentials. Piromelatine (Neu-P11) also possesses pain-related P2X3, TRPV1, and Nav1.7 channel-inhibition capacities .

HY-17038B

Agomelatine (L(+)-Tartaric acid) 4 Publications Verification S-20098 L(+)-Tartaric acid	Melatonin Receptor 5-HT Receptor Endogenous Metabolite	Neurological Disease
Agomelatine L(+)-Tartaric acid (S-20098 L(+)-Tartaric acid) is a specific agonist of MT1 and *MT2* receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine L(+)-Tartaric acid is a selective 5-HT2C receptor antagonist with pK_is of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively .

HY-17038S1

Agomelatine-d4 S-20098-d₄	Isotope-Labeled Compounds Melatonin Receptor 5-HT Receptor Endogenous Metabolite	Neurological Disease
Agomelatine-d₄ is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2].

HY-17038R

Agomelatine (Standard)	Melatonin Receptor 5-HT Receptor Endogenous Metabolite	Neurological Disease
Agomelatine (Standard) is the analytical standard of Agomelatine. This product is intended for research and analytical applications. Agomelatine (S-20098) is a specific agonist of MT1 and *MT2* receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine is a selective 5-HT2C receptor antagonist with pK_is of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively .

HY-17038S2

Agomelatine-d3 S-20098-d₃	Melatonin Receptor 5-HT Receptor Endogenous Metabolite	Neurological Disease
Agomelatine-d₃ is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2].

HY-105285R

Piromelatine (Standard) Neu-P11 (Standard)	Melatonin Receptor 5-HT Receptor P2X Receptor TRP Channel Sodium Channel	Neurological Disease
Piromelatine (Standard) is the analytical standard of Piromelatine. This product is intended for research and analytical applications. Piromelatine (Neu-P11) is a melatonin MT1/MT2 receptor agonist, serotonin 5-HT1A/5-HT1D agonist, and serotonin 5-HT2B antagonist. Piromelatine (Neu-P11) possesses sleep promoting, analgesic, anti-neurodegenerative, anxiolytic and antidepressant potentials. Piromelatine (Neu-P11) also possesses pain-related P2X3, TRPV1, and Nav1.7 channel-inhibition capacities .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-17038A

Agomelatine hydrochloride 4 Publications Verification S-20098 hydrochloride	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Melatonin Receptor 5-HT Receptor Endogenous Metabolite
Agomelatine hydrochloride (S-20098 hydrochloride) is a specific agonist of MT1 and *MT2* receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine hydrochloride is a selective 5-HT2C receptor antagonist with pK_is of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively .

HY-17038

Agomelatine 4 Publications Verification S-20098	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Melatonin Receptor 5-HT Receptor Endogenous Metabolite
Agomelatine (S-20098) is a specific agonist of MT1 and *MT2* receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine is a selective 5-HT2C receptor antagonist with pK_is of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively .

HY-17038B

Agomelatine (L(+)-Tartaric acid) 4 Publications Verification S-20098 L(+)-Tartaric acid	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Melatonin Receptor 5-HT Receptor Endogenous Metabolite
Agomelatine L(+)-Tartaric acid (S-20098 L(+)-Tartaric acid) is a specific agonist of MT1 and *MT2* receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine L(+)-Tartaric acid is a selective 5-HT2C receptor antagonist with pK_is of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively .

HY-17038R

Agomelatine (Standard)	Structural Classification Alkaloids Other Alkaloids Source classification Endogenous metabolite	Melatonin Receptor 5-HT Receptor Endogenous Metabolite
Agomelatine (Standard) is the analytical standard of Agomelatine. This product is intended for research and analytical applications. Agomelatine (S-20098) is a specific agonist of MT1 and *MT2* receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine is a selective 5-HT2C receptor antagonist with pK_is of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively .

Cat. No.	Product Name	Chemical Structure

HY-17038S

Agomelatine-d6
Agomelatine-d₆ is deuterium labeled Agomelatine. Agomelatine is a specific agonist of MT1 and MT2 receptors[1] .

HY-103005S

Ramelteon metabolite M-II-d3
Ramelteon metabolite M-II-d₃ is the deuterium labeled Ramelteon metabolite M-II. Ramelteon metabolite M-II is the major metabolite of Ramelteon, with IC50s of 208 pM, 1470 pM for human melatonin receptors (MT1 or MT2). Ramelteon is a selective melatonin agonist[1][2].

HY-17038S2

Agomelatine-d3
Agomelatine-d₃ is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2].

HY-14803S

Tasimelteon-d5
Tasimelteon-d₅ is the deuterium labeled Tasimelteon. Tasimelteon (BMS-214778) is an orally active and selective dual melatonin receptor agonist (DMRA). Tasimelteon has 2.1-4.4 times greater affinity for the MT2 receptor than for the MT1 receptor. Tasimelteon is a circadian regulator and has the potential for Non-24-Hour Sleep-Wake Disorder (Non-24)[1][2].

HY-17038S1

Agomelatine-d4
Agomelatine-d₄ is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

MT2 receptor

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products